Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s40123-021-00338-1
- Scopus: eid_2-s2.0-85102308192
- PMID: 33675508
- WOS: WOS:000625727700002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders
Title | Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders |
---|---|
Authors | |
Keywords | Autoimmune disorders COVID-19 Inflammatory eye disease Ophthalmic considerations Pandemic |
Issue Date | 2021 |
Publisher | Springer (part of Springer Nature): Fully open access journals - CC BY-NC. The Journal's web site is located at https://link.springer.com/journal/40123 |
Citation | Ophthalmology and Therapy, 2021, v. 10, p. 201-209 How to Cite? |
Abstract | The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies. |
Persistent Identifier | http://hdl.handle.net/10722/297671 |
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 1.158 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chau, CYC | - |
dc.contributor.author | Chow, LLW | - |
dc.contributor.author | Sridhar, S | - |
dc.contributor.author | Shih, KC | - |
dc.date.accessioned | 2021-03-23T04:20:08Z | - |
dc.date.available | 2021-03-23T04:20:08Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Ophthalmology and Therapy, 2021, v. 10, p. 201-209 | - |
dc.identifier.issn | 2193-8245 | - |
dc.identifier.uri | http://hdl.handle.net/10722/297671 | - |
dc.description.abstract | The global impact imposed by the coronavirus disease 2019 (COVID-19) pandemic may be soon alleviated by the introduction and worldwide dissemination of safe and effective vaccines. This expedited timetable for development and approval of COVID-19 vaccines is an unprecedented extraordinary, concerted achievement by the scientific community. With the pending global rollout of vaccines, each with different mechanisms of action, physicians of various specialties will need to identify vulnerable patient groups for special considerations or advice. In this commentary, we analyse the important considerations for COVID-19 vaccines in patients with inflammatory eye diseases. Scrutiny of immunogenicity and adverse effects, particularly antibody-dependent enhancement, would better help in counselling these patients undergoing vaccination. More research on pharmacovigilance would allow for tailored guidelines and personalised management strategies. | - |
dc.language | eng | - |
dc.publisher | Springer (part of Springer Nature): Fully open access journals - CC BY-NC. The Journal's web site is located at https://link.springer.com/journal/40123 | - |
dc.relation.ispartof | Ophthalmology and Therapy | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Autoimmune disorders | - |
dc.subject | COVID-19 | - |
dc.subject | Inflammatory eye disease | - |
dc.subject | Ophthalmic considerations | - |
dc.subject | Pandemic | - |
dc.title | Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders | - |
dc.type | Article | - |
dc.identifier.email | Chow, LLW: llwchow@hku.hk | - |
dc.identifier.email | Sridhar, S: sid8998@hku.hk | - |
dc.identifier.email | Shih, KC: kcshih@hku.hk | - |
dc.identifier.authority | Chow, LLW=rp02683 | - |
dc.identifier.authority | Sridhar, S=rp02249 | - |
dc.identifier.authority | Shih, KC=rp01374 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1007/s40123-021-00338-1 | - |
dc.identifier.pmid | 33675508 | - |
dc.identifier.pmcid | PMC7936587 | - |
dc.identifier.scopus | eid_2-s2.0-85102308192 | - |
dc.identifier.hkuros | 321751 | - |
dc.identifier.volume | 10 | - |
dc.identifier.spage | 201 | - |
dc.identifier.epage | 209 | - |
dc.identifier.isi | WOS:000625727700002 | - |
dc.publisher.place | New Zealand | - |